Photo of Douglas Dahl from massgeneral.org
Sep 10, 2024, 18:02
Radiation and Chemotherapy After Surgery as a Viable Alternative to Radical Cystectomy in Recurrent Bladder Cancer – NRG Oncology
NRG Oncology shared a post on LinkedIn:
“Press release: NRG Oncology Study Results Indicate that Radiation and Chemotherapy After Surgery Could be a Viable Alternative to Radical Cystectomy for Patients with Recurrent Bladder Cancer.”
Read further.
Source: NRG Oncology/LinkedIn
Douglas M. Dahl, MD, FACS, is the Chief of Urologic Oncology and a urologic surgeon at Massachusetts General Hospital. He specializes in the treatment of genitourinary cancers, minimally invasive surgical techniques, and related research. He serves as the Chief of the Division of Urologic Oncology, Clinical Co-Director of The Claire and John Bertucci Center for Genitourinary Cancers, and is also an Associate Urologist.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 12, 2025, 08:00
Aug 12, 2025, 04:55
Aug 12, 2025, 04:26
Aug 11, 2025, 22:32
Aug 11, 2025, 21:07